Factors Influencing COVID-19 Risk: Insights from Molnupiravir Exposure-Response Modeling of Clinical Outcomes
Description
Molnupiravir (MOV) is an oral antiviral for the treatment of COVID-19 in outpatient settings. This analysis investigated the relationship between β-D-N4-hydroxycytidine (NHC) pharmacokinetics (PK) and clinical outcomes in patients with mild to